July 2026
Learning Objectives
By completing this eLearning module:
-
- Identify high-risk populations and implement strategies for early diagnosis in high-risk groups.
- Explain and apply guideline recommendations consistently in practice.
- Discuss genetic influences on IgAN and incorporate genetic considerations into treatment planning.
- Describe new treatment pathways and integrate novel therapies into practice where appropriate.
Activity Disclosures
This activity is supported by Otsuka America Pharmaceutical, Inc.
Faculty Disclosures
Fernando C. Fervenza, MD, Ph.D., FASN
Research Grant Support to Mayo Clinic: Genentech/Roche, Janssen Pharmaceutical, Amgen
Consulting: Alexion Pharmaceutical, Novartis, Otsuka, Astellas Pharma Global, Takeda, Boehringer Ingelheim, Vera Therapeutics,Travere, Vertex Pharmaceuticals, Apellis Pharmaceuticals.
Mariela Navarro- Torres, MD
Consulting: Travere, Novartis
Speaker: Vera Therapeutics, Vertex, Apellis
Pietro Canetta, MD, MS, FASN
Consulting: Takeda, Travere, Vera, Novartis, Calliditas
Data safety monitoring board: Otsuka
Clinical trial participation: Calliditas, Travere, Novartis, Vera, Sanofi, Apellis
The faculty member(s) involved in this activity received a standard, nominal honorarium for their role in the preparation and delivery of this activity.
All planners and reviewers involved in the development of this activity declared no relevant financial relationships with ineligible companies.
Disclaimers
This activity underwent review in line with standards of editorial integrity and publication ethics. Potential conflicts of interest have been identified and resolved in accordance with John Wiley and Sons, Inc.’s Policy on Activity Disclosure and Conflict of Interest. The primary resolution method was review by an unconflicted expert. For information about the accreditation of this program, please contact [email protected].
Parts of this program’s content were developed using Claude Opus 4.7 (July 2026). All materials were reviewed and approved by the Wiley content strategist team and an external peer reviewer. No clinical material was created with the use of Claude or any other artificial intelligence.
Accreditation
John Wiley & Sons, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
John Wiley and Sons, Inc. designates this enduring material based CME activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity. For information on applicability and acceptance of continuing medical education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within 30 minutes and complete the activity during the valid credit period, which is up to three years from initial publication. Additionally, up to 3 attempts and a score of 75% or higher is needed to pass the post-test and claim credit. You will need to log into your Wiley Health Learning account (registration is free) to complete this activity and earn a certificate.
To begin, please click the Pre-test button below to contribute to our outcomes data then proceed to the course content.
